uniQure NV

uniQure NV, a small-cap biotechnology firm, opened with a notable loss today, contrasting with the S&P 500's modest decline. Over the past month, uniQure's performance has significantly deteriorated. Technical indicators suggest a bearish sentiment, and the company is currently loss-making with no dividend yield.

uniQure NV has faced notable volatility, with a significant stock decline today and a steep drop over the past week and month. Financial metrics reveal challenges, including a substantial decrease in net sales and a negative pre-tax profit. The company's market capitalization stands at USD 1,443 million, raising concerns about its operational stability.

uniQure NV has faced significant stock volatility, hitting an intraday low and experiencing substantial declines over various timeframes. Despite a yearly increase, its year-to-date performance is negative. Financial metrics reveal challenges, including decreased net sales and a notable pre-tax loss, indicating operational inefficiencies amid broader market trends.

uniQure NV experienced a significant decline in its stock price today, contrasting with the modest gain of the S&P 500. The company has faced a notable downturn over the past month, with key financial metrics indicating a loss-making position and a premium valuation relative to its book value.

uniQure NV, a small-cap biotechnology firm, experienced a notable decline in its stock performance today, reflecting a significant downturn over the past month. Technical indicators present a mixed outlook, with contrasting signals from MACD and Bollinger Bands. The company's financial metrics reveal a complex situation for stakeholders.

uniQure NV's stock surged significantly today, contrasting with the modest rise of the S&P 500. Despite recent challenges, including a decline over the past week and month, the company has achieved impressive one-year returns. However, it faces operational difficulties, including negative EBITDA and debt servicing issues.

uniQure NV, a small-cap biotechnology firm, saw a notable intraday gain today, contrasting with the S&P 500's modest rise. Despite a remarkable annual return, the company faces significant challenges, including operating losses, declining net sales, and a negative EBITDA, raising concerns about its financial stability.

uniQure NV has faced notable volatility, with a significant stock decline today and a staggering drop over the past week. Financial metrics indicate challenges, including negative EBITDA and a low EBIT to interest ratio. The company's recent net sales also fell sharply, raising concerns about its market position.

uniQure NV, a small-cap biotechnology firm, opened with a notable loss, continuing a trend of significant declines over the past month. The company, which has a market capitalization of around USD 956 million and is currently loss-making, exhibits a unique financial structure with a high return on equity.

uniQure NV faced significant stock volatility, dropping 24% in a challenging trading environment. The company reported a 52.71% decline in net sales, contributing to concerns about financial stability, including negative EBITDA and a troubling return on capital employed. Its operational inefficiencies further complicate its market position.

uniQure NV has faced notable volatility, with a significant stock decline today and over the past week. Despite a remarkable year-over-year growth, the company is grappling with financial challenges, including operating losses and a substantial drop in net sales, raising concerns about its financial health.

uniQure NV achieved a new 52-week high of USD 61.79 on October 8, 2025, reflecting a remarkable 1014.68% increase over the past year. Despite being a loss-making small-cap company in the Pharmaceuticals & Biotechnology sector, it has a market capitalization of USD 956 million and notable financial metrics.

uniQure NV, a small-cap biotechnology firm, saw its stock rise significantly on October 7, 2025, amid broader market gains. Despite impressive short-term stock performance, the company faces challenges, including a sharp decline in net sales and negative EBITDA, raising concerns about its financial health and debt servicing capabilities.

uniQure NV has achieved a new 52-week high of USD 55.11, reflecting a remarkable growth of 909.48% in its stock price over the past year. With a market capitalization of USD 956 million, the company demonstrates effective management despite being loss-making and not offering dividends.

uniQure NV achieved a new 52-week high of USD 54.98 on September 25, 2025, reflecting an impressive 878.62% increase over the past year. Despite being a loss-making microcap in the Pharmaceuticals & Biotechnology industry, the company has a market capitalization of USD 956 million and strong financial metrics.

uniQure NV achieved a new 52-week high of USD 51.21 on September 24, 2025, reflecting a significant growth trajectory from its previous low. The company, operating in the Pharmaceuticals & Biotechnology sector, has shown remarkable one-year performance, despite being loss-making and lacking a dividend yield.

uniQure NV faced notable volatility on September 15, 2025, with a significant stock price decline. The company reported a sharp drop in net sales and ongoing operating losses, raising concerns about its financial health. Despite a strong one-year return, its long-term outlook remains uncertain.